BH3模拟物抑制BCL-XL可诱导EBV相关T/NK细胞淋巴瘤模型凋亡
本研究建立ENKTL和CAEBV来源的细胞系作为临床前模型,发现这些细胞对DNA损伤诱导的细胞死亡耐药,但BCL-XL特异性抑制剂A-1331852可诱导凋亡,且同时靶向MCL-1时效果更佳,异种移植模型证实A-1331852体内治疗有益。
要点
- ENKTL和CAEBV细胞系对DNA损伤诱导的细胞死亡耐药,与P-糖蛋白外排泵功能无关
- BCL-XL特异性BH3模拟物A-1331852可诱导ENKTL和CAEBV细胞系凋亡
- 同时靶向MCL-1(BH3模拟物或基因敲除)可增强A-1331852诱导的凋亡
核心结论
- 靶向BCL-XL的治疗可能对EBV驱动的T/NK增殖性疾病患者有效,但MCL-1可能是潜在耐药因子。
研究设计与样本
- 研究建立了ENKTL和CAEBV来源的细胞系作为临床前模型,这些细胞系呈IL-2依赖且EBV潜伏II型基因表达模式。
主要发现
- 所有细胞系对DNA损伤诱导的细胞死亡耐药,且耐药与P-糖蛋白功能无关。
- A-1331852(特异性抑制BCL-XL的BH3模拟物)可一致地诱导凋亡。
- 同时靶向MCL-1(BH3模拟物或基因敲除)时A-1331852诱导的凋亡最有效。
- SNK6细胞系异种移植模型显示A-1331852治疗可能具有体内治疗益处。
临床怎么用
- 对于EBV相关T/NK细胞淋巴瘤患者,靶向BCL-XL可能是一种治疗策略,但需考虑MCL-1介导的耐药。
局限性
- 研究基于细胞系和异种移植模型,样本量未报告,需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Epstein-Barr virus (EBV)-associated T- and natural killer (NK)-cell malignancies, such as extranodal NK-/T-cell lymphoma (ENKTL), exhibit high chemoresistance and, accordingly, such patients have a poor prognosis. The rare nature of such cancers and nonmalignant T/NK lymphoproliferative disorders, such as chronic active EBV (CAEBV), has limited our understanding of the pathogenesis of these diseases. Here, we characterize a panel of ENKTL- and CAEBV-derived cell lines that had been established from human tumors to be used as preclinical models of these diseases. These cell lines were interleukin-2 dependent and found to carry EBV in a latency II gene-expression pattern. All cell lines demonstrated resistance to cell death induction by DNA damage-inducing agents, the current standard of care for patients with these malignancies. This resistance was not correlated with the function of the multidrug efflux pump, P-glycoprotein. However, apoptotic cell death could be consistently induced following treatment with A-1331852, a BH3-mimetic drug that specifically inhibits the prosurvival protein BCL-XL. A-1331852-induced apoptosis was most efficacious when prosurvival MCL-1 was additionally targeted, either by BH3-mimetics or genetic deletion. Xenograft models established from the ENKTL cell line SNK6 provided evidence that A-1331852 treatment could be therapeutically beneficial in vivo. The data here suggest that therapeutic targeting of BCL-XL would be effective for patients with EBV-driven T/NK proliferative diseases, however, MCL-1 could be a potential resistance factor.
引用
- Sejic N, George LC, Tierney RJ, et al. BCL-XL inhibition by BH3-mimetic drugs induces apoptosis in models of Epstein-Barr virus-associated T/NK-cell lymphoma. Blood Adv. 2020. PMID: 33017468. doi:10.1182/bloodadvances.2020002446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。